Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting
May 25 2023 - 4:05PM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule product candidates to address serious
diseases, including oncology, non-alcoholic steatohepatitis (NASH)
and obesity, today announced that the TERN-701 (HS-10382)
trial-in-progress (TiP) abstract is now available on the 2023
American Society of Clinical Oncology (ASCO) Annual Meeting
website. The ASCO Annual Meeting will be held in person at
McCormick Place in Chicago, Illinois, and online from June 2 - 6,
2023.
The TiP abstract details that patient enrollment
reached Cohort 3 of the Dose Escalation phase as of February 2023,
with seven participating study sites in China. The TiP poster
highlights completion of enrollment of Cohort 5 as of April
2023.
Following are details of the upcoming TERN-701
TiP poster presentation:
Abstract Title: |
|
A
Phase 1, multicenter, open-label, dose-escalation and
dose-expansion study to evaluate the safety, tolerability,
pharmacokinetics (PK), and efficacy of HS-10382 (TERN-701) in
patients (pts) with chronic myeloid leukemia (CML) |
Abstract
# |
|
TPS7081 |
Presenter: |
|
Jiawei Wei, MD, PhD, Hansoh
Pharmaceuticals Group Co. Ltd |
Poster
Session: |
|
Hematologic Malignancies –
Leukemia, Myelodysplastic Syndromes, and Allotransplant |
Date/Time: |
|
Monday, June 5, 2023 from 8:00
AM-11:00 AM CT |
“We are encouraged by the speed at which our
partner Hansoh has progressed the dose escalation part of the Phase
1 trial in China. This reaffirms our hope that we could potentially
see data accepted for presentation later this year,” said Sen
Sundaram, chief executive officer at Terns. “In addition to our
planned virtual CML R&D event in July, we also look forward to
the initiation of our Phase 1 U.S. clinical trial of TERN-701 in
the second half of this year.”
The full abstract of the TERN-701 poster is
available online at: ASCO.org/abstracts.
About Terns
PharmaceuticalsTerns Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company developing a portfolio of
small-molecule product candidates to address serious diseases,
including oncology, NASH and obesity. Terns’ pipeline includes two
clinical stage development programs including an allosteric BCR-ABL
inhibitor and a THR-β agonist (+/- an FXR agonist), and preclinical
small-molecule GLP-1 receptor agonist and GIPR modulator programs.
For more information, please visit: www.ternspharma.com.
Cautionary Note Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements about Terns Pharmaceuticals, Inc. (the
“Company,” “we,” “us,” or “our”) within the meaning of the federal
securities laws, including those related to the Company’s
expectations of timing and potential results of the clinical trials
and other development activities of the Company and its partners;
the potential indications to be targeted by the Company with its
small-molecule product candidates; the therapeutic potential of the
Company’s small-molecule product candidates; the potential for the
mechanisms of action of the Company’s product candidates to be
therapeutic targets for their targeted indications; the potential
utility and progress of the Company’s product candidates in their
targeted indications, including the clinical utility of the data
from and the endpoints used in the Company’s clinical trials; the
Company’s clinical development plans and activities, including the
results of any interactions with regulatory authorities on its
programs; the Company’s expectations regarding the profile of its
product candidates, including efficacy, tolerability, safety,
metabolic stability and pharmacokinetic profile and potential
differentiation as compared to other products or product
candidates; the Company’s plans for and ability to continue to
execute on its current development strategy, including potential
combinations involving multiple product candidates; the impact of
new legislation and regulatory developments on the Company’s plans
for its product candidates, such as the effect of the Inflation
Reduction Act of 2022; and the Company’s expectations with regard
to its cash runway and sufficiency of its cash resources. All
statements other than statements of historical facts contained in
this press release, including statements regarding the Company’s
strategy, future financial condition, future operations, future
trial results, projected costs, prospects, plans, objectives of
management and expected market growth, are forward-looking
statements. In some cases, you can identify forward-looking
statements by terminology such as “aim,” “anticipate,” “assume,”
“believe,” “contemplate,” “continue,” “could,” “design,” “due,”
“estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“positioned,” “potential,” “predict,” “seek,” “should,” “target,”
“will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of
these terms or other comparable terminology. The Company has based
these forward-looking statements largely on its current
expectations, estimates, forecasts and projections about future
events and financial trends that it believes may affect its
financial condition, results of operations, business strategy and
financial needs. In light of the significant uncertainties in these
forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. These
statements are subject to risks and uncertainties that could cause
the actual results and the implementation of the Company’s plans to
vary materially, including the risks associated with the
initiation, cost, timing, progress, results and utility of the
Company’s current and future research and development activities
and preclinical studies and clinical trials. These risks are not
exhaustive. For a detailed discussion of the risk factors that
could affect the Company’s actual results, please refer to the risk
factors identified in the Company’s SEC reports, including but not
limited to its Annual Report on Form 10-K for the year ended
December 31, 2022. Except as required by law, the Company
undertakes no obligation to update publicly any forward-looking
statements for any reason.
Contacts for Terns
InvestorsJustin
Nginvestors@ternspharma.com
MediaJenna UrbanBerry &
Company Public Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Apr 2024 to May 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From May 2023 to May 2024